Logo do repositório
 
Publicação

Development and characterization of a new plasmid delivery system based on chitosan–sodium deoxycholate nanoparticles

2012-03-12Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorCadete, A.
dc.contributor.authorFigueiredo, L.
dc.contributor.authorLopes, R.
dc.contributor.authorCalado, Cecília
dc.contributor.authorAlmeida, A. J.
dc.contributor.authorGonçalves, L. M. D.
dc.date.accessioned2020-09-16T15:18:19Z
dc.date.available2020-09-16T15:18:19Z
dc.date.issued2012-03-12
dc.description.abstractChitosan is one of the most promising polymers for drug delivery through the mucosal routes because of its polycationic, biocompatible, and biodegradable nature, and particularly due to its mucoadhesive and permeation-enhancing properties. Bile salts are known to interact with lipid membranes, increasing their permeability. The addition of bile salts to chitosan matrices may improve the delivery characteristics of the system, making it suitable for mucosal administration of bioactive substances. In the present study we have developed chitosan nanoparticles using sodium deoxycholate as a counter ion and evaluated their potential as gene delivery carriers. Chitosan–sodium deoxycholate nanoparticles (CS/DS) obtained via a mild ionic gelation procedure using different weight ratios were used to encapsulate plasmid DNA (pDNA) expressing a “humanized” secreted Gaussia Luciferase as reporter gene (pGLuc, 5.7 kDa). Mean particle size, polydispersity index and zeta potential were evaluated in order to select the best formulation for further in vitro studies. The nanoparticles presented an average size of 153–403 nm and a positive zeta potential ranging from +33.0 to +56.9 mV, for nanoparticles produced with CS/DS ratios from 1:4 to 1:0.6 (w:w), respectively. The pDNA was efficiently encapsulated and AFM studies showed that pDNA-loaded nanoparticles presented a more irregular surface due to the interaction between cationic chitosan and negatively charged pDNA which results in a more compact structure when compared to empty nanoparticles. Transfection efficiency of CS/DS–pDNA nanoparticles into moderately (AGS) and well differentiated (N87) gastric adenocarcinoma cell lines was determined by measuring the expression of luciferase, while cell viability was assessed using the MTT reduction. The CS/DS nanoparticles containing encapsulated pDNA were able to transfect both AGS and N87 cell lines, being more effective with AGS cells, the less differentiated cell line. The highest enzymatic activity was achieved with 20% pDNA encapsulated and after 24 h of transfection time. Low cytotoxicity was observed for the CS/DS nanoparticles either with or without pDNA, suggesting this could be a new potential vehicle for mucosal delivery of pDNA.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCADETE, A.; [et al] – Development and characterization of a new plasmid delivery system based on chitosan–sodium deoxycholate nanoparticles. European Journal of Pharmaceutical Sciences. ISSN 0928-0987. Vol. 45, N.º 4 (2012), pp. 451-458pt_PT
dc.identifier.doi10.1016/j.ejps.2011.09.018pt_PT
dc.identifier.issn0928-0987
dc.identifier.urihttp://hdl.handle.net/10400.21/12241
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://reader.elsevier.com/reader/sd/pii/S092809871100337X?token=924A830C9830CA5E77B005220E537ECEC56C0CDD5800A144F820723C5F99D5ADD7A43280A633394BA89A4FA8C4D2CC8Apt_PT
dc.subjectNanoparticlespt_PT
dc.subjectChitosanpt_PT
dc.subjectSodium deoxycholatept_PT
dc.subjectIonic gelationpt_PT
dc.subjectGastric carcinoma cell linespt_PT
dc.titleDevelopment and characterization of a new plasmid delivery system based on chitosan–sodium deoxycholate nanoparticlespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberPTDC/BIO/69242/2006
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FBIO%2F69242%2F2006/PT
oaire.citation.endPage458pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage451pt_PT
oaire.citation.titleEuropean Journal of Pharmaceutical Sciencespt_PT
oaire.citation.volume45pt_PT
oaire.fundingStream3599-PPCDT
person.familyNameCalado
person.givenNameCecília
person.identifier130332
person.identifier.ciencia-id9418-E320-3177
person.identifier.orcid0000-0002-5264-9755
person.identifier.ridE-2102-2014
person.identifier.scopus-author-id6603163260
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicatione8577257-c64c-4481-9b2b-940fedb360cc
relation.isAuthorOfPublication.latestForDiscoverye8577257-c64c-4481-9b2b-940fedb360cc
relation.isProjectOfPublicatione934d4a3-07d0-4c5d-8183-e76b3b0bf237
relation.isProjectOfPublication.latestForDiscoverye934d4a3-07d0-4c5d-8183-e76b3b0bf237

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Development_CRCCalado.pdf
Tamanho:
656.17 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

ISEL - Eng. Quim. Biol. - Artigos